Curi Bio
Founded 2015 Β· 1 known investors
Curi Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency. It serves pharmaceutical and biotech R&D teams working on drug discovery.
AI & Machine LearningBiotechMedical Devices
Founders & leadership
Curi Bio was founded in 2015 by Elliot Fisher.
EF
Elliot FisherCofounder30 Under 30 2023
Investors Β· 1
Non-dilutive funding Β· 14 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $324.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $275.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $252.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $252.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $221.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $214K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Curi Bio do?
- Curi Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency. It serves pharmaceutical and biotech R&D teams working on drug discovery.
- Who founded Curi Bio?
- Curi Bio was founded by Elliot Fisher in 2015.
- Who are Curi Bio's investors?
- Curi Bio's investors include Dynamk Capital.